Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.

Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.

Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.